trial · primary record
E. coli CD-expressing genetically modified neural stem cells
Adult Anaplastic Astrocytoma
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 16 |
| Primary completion | 2017-10-07 |
| Primary endpoint | Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) |
| Registry ID | NCT02015819 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:42.248Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02015819
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.